Masupirdine

Summary

Masupirdine (CHEMBL4117187) is a phase-3 clinical-stage small molecule; indicated across 1 condition including alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 3
• Chemistry: 478.4 Da · C21H24BrN3O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4117187
Name	Masupirdine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	10073773
Molecular formula	C21H24BrN3O3S
Molecular weight	478.4
InChIKey	GWCYPEHWIZXYFZ-UHFFFAOYSA-N

SMILES: CN1CCN(CC1)CC2=CN(C3=C2C=C(C=C3)OC)S(=O)(=O)C4=CC=CC=C4Br

IUPAC name: 1-(2-bromophenyl)sulfonyl-5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]indole

Also known as: Masupirdina, Masupirdine, Suvn-502, SUVN-502, MASUPIRDINE

Parent form; salt/anhydrous children: CHEMBL4082473

Patent coverage: 57 distinct patent families (149 SureChEMBL compound mentions), from 3 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 6.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR6	8.69	Ki	2.04	nM	CHEMBL_ACT_28508135
HTR6	8.69	Ki	2.04	nM	CHEMBL_ACT_28620527
HTR6	8.69	Ki	2.04	nM	CHEMBL_ACT_28815809
HTR2A	6.42	Ki	377	nM	CHEMBL_ACT_28620536
HTR2A	5.6	Ki	2514	nM	CHEMBL_ACT_28508144
HTR2A	5.6	Ki	2514	nM	CHEMBL_ACT_28815818

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	2	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05397639	PHASE3	RECRUITING	Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer’s Type
NCT02580305	PHASE2	COMPLETED	SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer’s Disease- Phase 2a Study
NCT03564964	Not specified	NO_LONGER_AVAILABLE	Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer’s Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).